Valuation: Alector, Inc.

Market Cap 169M 148M 138M 127M 238M 16.16B 244M 1.64B 642M 8B 634M 620M 27.65B P/E 2026 *
-1.77x
P/E 2027 * -2.37x
Enterprise Value -78.38M -68.87M -64.28M -59M -110M -7.51B -113M -762M -298M -3.71B -294M -288M -12.84B EV / Sales 2026 *
-11.4x
EV / Sales 2027 * -6.89x
Free-Float
86.82%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 week-0.65%
Current month-24.38%
1 month-26.92%
3 months-33.91%
6 months-20.42%
Current year-2.56%
1 week 1.46
Extreme 1.455
1.58
1 month 1.37
Extreme 1.37
2.14
Current year 1.37
Extreme 1.37
2.74
1 year 1.09
Extreme 1.09
3.4
3 years 0.87
Extreme 0.87
9.06
5 years 0.87
Extreme 0.87
29.3
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 30/04/2013
Director of Finance/CFO 52 19/06/2025
Chief Tech/Sci/R&D Officer - 31/12/2016
Director TitleAgeSince
Director/Board Member 71 30/04/2013
Director/Board Member 72 30/09/2018
Chairman 77 12/06/2023
Date Insider Type Main position Quantity % Market Cap.
09/07/26 Free

Controller/Auditor

20,000 0.0180%
17/06/26 Free

Director

38,150 0.0344%
17/06/26 Free

Director

38,150 0.0344%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%-0.65%-5.59%-76.14% 169M
-1.93%-4.39%+45.64%+66.74% 55.2B
+2.83%+0.48%+28.18%+82.59% 55.6B
+0.54%+1.22%-16.62%-13.47% 23.51B
-0.97%-3.30%-1.79%+383.00% 22.35B
-4.01%-3.67%+13.17%-14.29% 20.6B
-1.06%-2.60%+26.72%-33.46% 17.45B
-3.34%-7.77%+23.78%+536.66% 15.16B
-2.09%+0.64%+49.78%+178.74% 13.91B
-3.14%-8.47%+165.37%+292.18% 13.74B
Average -1.27%-1.21%+32.86%+140.26% 23.77B
Weighted average by Cap. -0.70%-0.52%+32.47%+127.34%

Financials

2026 *2027 *
Net sales 6.86M 6.03M 5.62M 5.16M 9.66M 657M 9.9M 66.69M 26.08M 325M 25.74M 25.19M 1.12B 22.88M 20.11M 18.77M 17.22M 32.24M 2.19B 33.04M 223M 87.03M 1.08B 85.91M 84.04M 3.75B
Net income -94.11M -82.69M -77.19M -70.84M -133M -9.01B -136M -915M -358M -4.46B -353M -346M -15.42B -96.62M -84.9M -79.24M -72.73M -136M -9.25B -139M -940M -367M -4.58B -363M -355M -15.83B
Net Debt -247M -217M -203M -186M -348M -23.67B -357M -2.4B -940M -11.71B -928M -908M -40.49B -326M -287M -268M -246M -460M -31.26B -471M -3.17B -1.24B -15.47B -1.23B -1.2B -53.48B
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
29/07/26 US$1.520 0.00% 307,858
28/07/26 US$1.520 +0.66% 342,803
27/07/26 US$1.510 +2.03% 229,001
24/07/26 US$1.480 -0.67% 325,295
23/07/26 US$1.490 -2.61% 607,111
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
1.520USD
Average target price
3.100USD
Spread / Average Target
+103.95%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALEC Stock